Tokyo-21th, August, 2018, Mr. Jacky, Zhang, Executive Chairman of Beroni Group and Toyotaka Mori, President & CEO of I’rom Group Co., Ltd (“I’rom Group”) signed a strategic partnership agreement to share resources such as technology, research facilities and network of connections. One of the focus areas of this joint cooperation is in the business of genetic medicine and stem cell engineering using the vector technology owned by a subsidiary of I’rom Group, ID Pharmaceutical Co., Ltd.
I’rom Group was established in Tokyo in April 1997 and has got listed on the Tokyo Stock Exchange. It has since expanded into four business services – Advanced Medicinal Treatment Services, Site Management Organisation Services, Contract Research Organisation Services, and Medical Support Services. The Group has consistently been involved in each of these businesses with the objective of contributing to medical development and elevating the quality of life of patients.
I’rom Group is focusing its efforts on technical development and subsequent necessary clinical trials in the fields of gene therapy and regenerative medicine. Through its subsidiary, ID Pharmaceutical Co., Ltd, it has built a facility for the manufacture of GMP vector for use in gene therapy and regenerative medicine based on Sendai virus vector technology. The facility can be used to supply gene therapy formulations and vectors for use in clinical settings.
In 2016, I’rom Group acquired Australia-based CMAX Clinical Research Pty Ltd, one of Australia’s largest and most experienced Phase I-II clinical trial units located in Adelaide. CMAX is a pioneer clinical research center which has extensive practical experience in the support of early stage clinical trials including global large-scale clinical trials and FIH (First-In-Human) trials.
Mr. Jacky, Zhang, Executive Chairman of Beroni Group said: “ the ability to leverage on I’rom Group’s presence in both Japan and Australia with its state-of-the-art clinical research facilities will most certainly strengthen Beroni’s undertakings in growing its portfolio of biotechnologies and research initiatives. This cooperation will not only help advance our stem cell therapy technology but also accelerate our R&D clinical trials. It is a privilege to be working with such a leading specialist in the field of regenerative medicine.”
The cooperation between Beroni Group and I’rom Group aims to promote the the innovation and development of gene therapy, regenerative medicine and stem cell therapy. Beroni and I’rom Group may enter into further contractual agreements from time to time as and when the parties agree on specific collaboration projects.
Beroni Group will carry out in-depth deployment of the existing business structure based on the cooperation, and work on the research and development of regenerative medicine and stem cell therapy to treat cancer tumours. Beroni Group and I’rom Group with rich resources, excellent service experience and advanced technology will jointly advance cross-border cooperation in biotechnology, bring in innovative resources at home and abroad, integrate talents and technological innovations to promote the development of the group, and realize the deep integration of the medical industry and the real economy.
